Brazilian Universities Pioneer Blood Test for Early Breast Cancer Detection

Limitations of Traditional Screening and the Need for Innovation

Mammography, the gold standard for breast cancer screening, faces hurdles in Brazil. Recommended for women aged 50-69 via SUS, and recently extended to those over 40 under medical evaluation, it requires specialized equipment and trained radiologists, often unavailable in remote regions. Pain, radiation exposure, and false positives contribute to low participation rates, estimated below 50% in some areas. Moreover, mammography struggles to detect tumors in dense breasts common among younger women, where aggressive forms are rising.

This is where liquid biopsy emerges as a complementary tool. By analyzing tumor-derived biomarkers in blood—such as circulating tumor DNA (ctDNA), proteins, or exosomes—it offers a non-invasive alternative. Globally, tests like GRAIL's Galleri demonstrate potential for multi-cancer early detection, though regulatory hurdles remain.54 In Brazil, university-led research is adapting this to local needs, focusing on affordability and scalability.

Birth of the RosalindTest: A Brazilian University-Led Breakthrough

Developed through a partnership between biotech firm LiqSci and FMABC, the RosalindTest® honors Rosalind Franklin, the pioneering DNA researcher. This blood-based assay targets hypoxia-inducible factor 1-alpha (HIF-1α) and glucose transporter 1 (GLUT1), genes upregulated in low-oxygen tumor microenvironments, signaling early cancer development before imaging visibility.

The test's inception stems from doctoral work at USP and Unifesp, where geneticists dissected molecular pathways in breast tumors. Initial validation occurred in three clinical studies, achieving 95% accuracy in distinguishing cancerous from healthy cases—a figure validated in a Nature Scientific Reports publication.104 Unlike broad multi-cancer screens, it hones in on breast cancer specificity, ideal for targeted screening.

Decoding the Science: Step-by-Step Process of the RosalindTest

• Collection: Simple venous blood draw, no special prep needed.
• Extraction: Isolate RNA or proteins indicating gene expression changes.
• Analysis: Quantitative PCR or similar detects elevated HIF-1α/GLUT1 levels, hallmarks of hypoxic stress in nascent tumors.
• Result: Positive signals prompt confirmatory imaging/biopsy; negative reduces unnecessary procedures.

This process, refined at FMABC labs, leverages precision medicine principles, offering results in days versus weeks for tissue biopsies.

University Powerhouses Driving the Research

FMABC's Centro Universitário has been instrumental, hosting validation and pilot logistics. USP's genetic expertise, via PhD alumna Beatriz da Costa Aguiar Alves Reis, provided foundational tumor profiling. Unifesp contributed pharmacological insights from Glaucia Raquel Luciano da Veiga's doctoral thesis on biomarker dynamics. These institutions exemplify Brazil's higher education ecosystem fostering biotech spinouts like LiqSci, with FMABC earning royalties on commercialization.105

Such collaborations highlight universities' role in translating academia to societal impact, training next-gen researchers in oncology genomics.

Photo by Gustavo Sánchez on Unsplash

Pilot Deployment: Bringing Tech to Rural Brazil

In a landmark initiative, SENAR partnered with FMABC and LiqSci to screen 600 rural women in São Paulo and Ceará starting November 2025. Blood samples collected on-site were analyzed at FMABC, identifying at-risk individuals for SUS follow-up. This addresses Brazil's rural-urban divide, where mammography access lags, potentially saving lives by triaging high-risk cases efficiently.

Early feedback underscores feasibility: non-invasive, quick, and culturally sensitive, boosting participation among underserved farmers' wives.

Potential to Transform Brazilian Healthcare Landscape

Integration into SUS could expand screening beyond urban centers, aligning with INCA's push for equitable access. Cost-effective at scale, it complements mammography, reducing overload on imaging facilities. For younger women under 50—where incidence rises 10-15% yearly—it fills a critical gap. Economically, early detection averts billions in advanced treatment costs, per INCA models.

INCA projections emphasize urgency, positioning university innovations as national assets.

Expert Views: Promise Meets Prudence

Beatriz Aguiar notes, "We can't prevent cancer, but early diagnosis saves lives—less painful, more adherent." Mastologist José Carlos Sadalla praises the preliminary data but urges larger trials: "Promising Brazilian research, but test more patients for cross-cancer specificity." The Sociedade Brasileira de Mastologia (SBM) cautions no blood test replaces mammography yet, restricting to research protocols.51

This balanced discourse reflects academia's rigor, ensuring robust validation before rollout.

Global Context and Brazilian Edge

Worldwide, liquid biopsies like Galleri detect 50+ cancers but face scrutiny over false positives.57 RosalindTest's breast-specific focus yields higher precision, tailored to Brazil's epidemiology—higher triple-negative rates demanding early intervention. Universities' open-access ethos accelerates local adaptation versus proprietary foreign tech.

Foundational study on biomarkers underscores peer-reviewed credibility.

Implications for Higher Education and Research Careers in Brazil

This project spotlights Brazil's universities as biotech hubs, attracting funding like FAPESP grants. FMABC-USP-Unifesp synergy trains interdisciplinary talent in genomics, bioinformatics, and clinical trials—hot skills for research jobs. Aspiring academics can contribute via postdocs or faculty roles in oncology precision medicine.

Challenges include funding volatility, but successes like RosalindTest bolster case for sustained investment, positioning Brazil in global oncology innovation.

Photo by Gustavo Sánchez on Unsplash

Looking Ahead: Pathways to Widespread Adoption

Larger multicenter trials, ANVISA approval, and SUS integration loom next. Universities eye expansions to other cancers, leveraging AI for multi-biomarker panels. For women: Discuss with physicians; self-advocacy via university-led awareness campaigns empowers prevention.

Brazilian higher ed's role exemplifies how academia drives health equity, offering actionable hope amid rising incidence.